NL-OMON31969已完成4 期
A phase IV open label study in moderate to severe chronic plaque psoriasis subjects transitioning from previous systemic antipsoriasis therapies (methotrexate, cyclosporine, retinoids or PUVA, NBUVB) to Raptiva 1 mg/kg/ week therapy. - Open label trial investigating transition from systemic agents to Raptiva.
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Merck
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Mature subjects with moderate to severe chronic plaque-type psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporine, methotrexate and PUVA and meet all eligibility criteria will be eligible for the study.
- •Subjects must be willing and able to comply with the study requirements and give their written, informed consent.
排除标准
- •Subjects who have a contraindication to Raptiva, are participating in another clinical trial (except non-interventional studies, e.g. registries) or are experiencing an acute exacerbation of psoriasis at the time of screening will be excluded.
研究者
相似试验
进行中（未招募）
不适用
A Phase IV open label study in moderate to severe chronic plaque psoriasis subjects transitioning from previous systemic antipsoriasis therapies (methotrexate, cyclosporine, retinoids or PUVA, NBUVB) to Raptiva 1mg/kg/week therapy. - Open label trial investigating transition from systemic agents to RaptivaEUCTR2007-004243-29-NLMerck Serono International SA. An Affiliate of Merck KGaA, Darmstadt, Germany182
进行中（未招募）
不适用
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe DiseasePompe disease (acid alpha-glucosidase deficiency)MedDRA version: 17.1Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 100000004850EUCTR2015-000512-18-Outside-EU/EEAGenzyme Corporation Inc114
招募中
4 期
A collaborative, multicentre, national study for newly diagnosed patients with acute lymphoblastic leukaemiaCTRI/2015/12/006434Tata Medical Center Kolkata
进行中（未招募）
1 期
Post-marketing study of safety and efficacy of GARDASIL in young Japanese women.Human Papillomavirus infectionEUCTR2015-002932-42-Outside-EU/EEAMSD K.K., a subsidiary of Merck & Co., Inc1,000
进行中（未招募）
1 期
Will switching HIV-1-infected patients who have drug resistant HIV and stable on a regimen based on a protease inhibitor to another regimen based on the integrase inhibitor bictegravir be as equally effective?Human Immunodeficiency VirusMedDRA version: 20.1Level: LLTClassification code 10008919Term: Chronic HIV infectionSystem Organ Class: 100000004862EUCTR2018-004732-30-GBniversity of Sussex100